Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

NCT04165122 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Genitalis

Interventions

BIOLOGICAL: HDIT101
DRUG: Valaciclovir
BIOLOGICAL: HDIT101 placebo
DRUG: Valaciclovir placebo

Sponsor

Heidelberg ImmunoTherapeutics GmbH